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Worldwide, sudden cardiac death (SCD) is a major problem. It is most frequently caused by
ventricular tachyarrhythmias: Monomorphic and polymorphic ventricular tachycardia
(VT), torsade de pointes (TdP), and ventricular fibrillation (VF). Beta blockade, ACE inhibi-
tion, coronary reperfusion and other treatments have reduced the incidence of VT
but pulseless electrical activity (PEA) is increasingly seen, particularly in patients with
advanced chronic heart disease. From existing data, bradyarrhythmia in the form of
asystole (usually complete heart block without escape rhythm) causes only a minor pro-
portion (10e15%) of SCD. In patients aged 50 years and more, coronary artery disease plays
a dominant role causing more than 75% of SCD cases, either by acute ischemia and ven-
tricular fibrillation or by chronic scar formation and reentrant VT. In younger patients, SCD
may occur in patients with structurally normal hearts. A number of arrhythmogenic dis-
orders with an increased risk of SCD have been detected and better understood recently,
such as long and short QT syndrome, Brugada syndrome, catecholaminergic polymorphic
ventricular tachycardia, and the early repolarization syndrome. Most importantly, ECG
signs and clinical features indicating high risk for SCD have been identified. Knowledge of
the exact electrophysiologic mechanisms of ventricular tachyarrhythmias at the cellular
level has been improved and mechanisms such as phase 2 reentry and reflection proposed
to better understand why and how SCD occurs.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Definition of sudden cardiac death
Sudden cardiac death (SCD) has been defined as “natural
death due to cardiac causes, heralded by abrupt loss of con-
sciousness within one hour of the onset of acute symptoms;
pre-existing heart disease may have been known to be pre-
sent, but the time andmode of death are unexpected”.1 SCD is
therefore always non-traumatic and should be unexpected
and instantaneous. The delay between onset of symptoms
and (sudden) death has been defined differently over time,2014, Cardiological Sociefrom “within 24 hours” to “within 6 hours” and “within 1
hour”, which is the currently preferred definition.2
The term SCD is usually applied in cases where a patient
dies suddenly without any symptoms that indicate an immi-
nent risk of natural death within the next minutes. In fact,
25% of patients treated for out-of-hospital cardiac arrest had
literally no symptoms before the abrupt onset of SCD.3
It has been argued that in many cases of sudden death, the
cause is unknown and SCD due to an arrhythmic event is only
assumed, thus overestimating cardiac causes of sudden
death. However, autopsy studies in patients with suddenty of India. All rights reserved.
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cardiac disease and only approximately a quarter due to non-
cardiac causes, predominantly due to pulmonary embolism
(18%) aortic rupture (4%), and intracranial bleeding (3%).4
The term “arrhythmic death” has been used instead of
SCD, and the Hinkle-Thaler classification distinguishes only
arrhythmic and non-arrhythmic cardiac death.5 However,
these terms are not identical with SCD because patients may
die non-suddenly due to arrhythmias and not all sudden
deaths are due to arrhythmias. The term “sudden death” will
be replaced by SCD in this review to clarify that only cardiac
mechanisms are considered. In some instances, the term
“cardiac arrest” or “aborted SCD” will be used to clarify that
survivors of SCD are included.2. Causes of sudden cardiac death:
arrhythmias and underlying pathology
2.1. Underlying arrhythmias
If an ECG documentation is available at the time of sudden
loss of consciousness, it shows ventricular fibrillation (VF) in
75%e80%, only rarely (10%e15%) bradyarrhythmia; in 5%e
10% the ECG does not show an arrhythmia (Fig. 1).2,6
Bradyarrhythmias lead to sudden death only in rare cases
because in most patients, endogenous release of catechol-
amines generates and sustains an escape rhythm that is suf-
ficient to keep the patient alive. In contrast, endogenous
catecholamine release triggered by circulatory collapse due to
ventricular tachyarrhythmias rather deteriorates the
situation.
In patients with an implantable cardioverter-defibrillator
(ICD), up to 80% of all device-treated ventricular tachyar-
rhythmias are monomorphic ventricular tachycardia (VT).7
Ventricular tachycardia (VT) is presumed to represent the
typical initial arrhythmia in patients with a myocardial scar
after infarction. However, monomorphic VT usually does notFig. 1 e Synopsis of the type of arrhythmia documented as
the first rhythm at the time of out-of-hospital SCD. The
published prevalence ranges widely in different studies
and registries. Different forms of VT/VF taken together
(four red to orange slices) account for 75% of documented
rhythms. Mono VT: monomorphic ventricular tachycardia,
PEA: pulseless electrical activity, poly VT: polymorphic
ventricular tachycardia, TdP: torsade de pointes, VF:
ventricular fibrillation.lead to loss of consciousness or SCD. In 100 patients with
stable VT, systolic blood pressure remained at 110 mmHg
despite a mean VT duration of 41 minutes at a rate of 188 bpm
and the fact that patients had a mean left ventricular ejection
fraction of 27%.8 Monomorphic VT leads to SCD only if other
special conditions contribute to an insufficient circulation or if
it degenerates into polymorphic VT or ventricular fibrillation
(VF).
Polymorphic VT is a very rare finding on Holter tapes
(prevalence 0.15%9) but caused up to 40% of SCD that occurred
in-hospital during rhythm monitoring.10,11 Polymorphic VT
was inducible in 15e20% of survivors of SCD who underwent
an electrophysiological study.12,13
Polymorphic VT is estimated to be the cause of SCD in
approximately 25% of the cases and is particularly frequent in
acute myocardial ischemia. Additionally, it is the typical
arrhythmia in catecholaminergic polymorphic VT (CPVT), an
inherited arrhythmogenic disorder characterized by adrener-
gically mediated polymorphic ventricular tachyarrhythmias.
Torsade de pointes (TdP) tachycardia is a form of poly-
morphic VT characterized by a gradual change in the QRS
amplitude and twisting of the QRS vector around the iso-
electric line. TdP is frequently associated with a prolonged QT
interval. It can terminate spontaneously; recur in non-
sustained spells, or degenerate into VF. It may be caused by
QT-prolonging drugs, ischemia, or may be due to inherited
long QT syndromes. It is 2e3 times more frequent in women;
advanced age, bradycardia, hypokalemia, hypomagnesemia,
left ventricular systolic dysfunction, renal and liver disease
(both leading to elevated plasma concentrations of causative
drugs) represent risk factors for drug-induced TdP. Patients
with advanced heart failure and a history of drug-induced TdP
had a significantly higher SCD risk during therapy with
amiodarone.
Ventricular flutter and VF are responsible for 23% of out-of-
hospital cardiac arrests treated by the emergency medical
system.14 VF can result from an initial VT that degenerated
into less organized rhythms. However, SCD may also result
from primary VF caused by acute myocardial ischemia or due
to inherited channelopathies such as Brugada or long QT
syndrome.
Pulseless electrical activity (PEA) is usually defined as the
presence of spontaneous organized cardiac electric activity in
the absence of blood flow sufficient to maintain conscious-
ness and (to distinguish it from e.g. vasovagal syncope)
absence of a rapid spontaneous return of adequate organ
perfusion and consciousness.15 Clinically, PEA is character-
ized by the absence of a palpable pulse in an unconscious
patient with organized electric activity other than ventricular
tachyarrhythmia on the ECG. The definition of PEA does not
include the agonal pattern of slow, very wide QRS complexes
at the end of a prolonged cardiac arrest. The incidence of PEA
as the first documented rhythm in patients with SCD is
increasing, potentially due to the ICD therapy, beta blockers
and other drugs in heart failure that reduce the risk of VT and
VF while not changing the risk of PEA. Additionally, patients
with very advanced heart disease may be more likely to
develop PEA than VT/VF which is supported by the observa-
tion of a higher incidence of PEA in nursing homes compared
to public locations.15 Even in patients with PEA who survived
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particularly low with approximately 8%.15
The exact pathophysiology of PEA is not clear. Likely, acute
(severe) myocardial ischemia may play a role, and a third of
patients with PEA have PCI performed during STEMI.16 Also
hypoxia may play a role since pulmonary disease is a signifi-
cant independent predictor and three fold more likely to be
associated with PEA than with VT/VF in men.15,17 Older age is
associated with PEA and asystole as SCD mechanism15
Women have a survival advantage over men for SCD resus-
citation outcomes but with a higher risk of PEA. The role of
medication in PEA is not clear. A retrospective study (univar-
iate analysis, not adjusted for other parameters) reported that
49% of patients with PEA were on b-blockers compared with
20% of VF patients.18 Antipsychotic drugs are an independent
risk factor for PEA, potentially related to their negative
inotropic effects.152.2. Underlying heart disease
SCD can occur at any age, and with or without detectable
(“structural”) heart disease.While coronary artery disease and
ischemic cardiomyopathy are the predominant cause of SCD
in patients aged 50 years and above, a number of more rare
diseases can cause SCD in younger populations (Table 1).
Coronary heart disease is the most frequent cause of SCD
with acute coronary lesions (ruptured plaque, coronary
thrombosis) detected at autopsy in 20e80% cases.2 It is
particularly frequent in patients >65 years of age and more
likely as the cause of SCD if symptoms of ischemia are present
and the longer (up to 1 hour) they persist before loss of con-
sciousness. Acutemyocardial ischemia is considered to be the
most important cause of SCD. It is most frequently (>60%)
associated with primary VF but also TdP, bradyarrhythmias
and monomorphic VT as the primary arrhythmia have beenTable 1 e Causes of SCD in patients above and below 50
years of age. Approximations with potential bias (data
from young patients mainly from US and European
registries on SCD in athletes19e22).
Patients ‡50 years
Coronary artery disease, ischemic cardiomyopathy
- Acute ischemia 75%e80%
- Chronic ischemia
- Scar-related VT
- Ventricular remodeling
Dilative cardiomyopathy 15%e20%
Others (hypertensive heart disease, aortic stenosis,
myocarditis, etc.)
5%e10%
Patients<50 years
Hypertrophic cardiomyopathy 5%e30%
Arrhythmogenic right ventricular cardiomyopathy 5%e25%
Myocarditis 6%e10%
Coronary artery disease 5%e20%
Coronary anomalies (incl. tunneled LAD) 2%e20%
Valvular heart disease (MVP, congenital HD, aortic
stenosis, etc.)
5%e10%
Dilative cardiomyopathy 2%e4%
Channelopathies (Brugada syndrome, LQTS, SQTS,
CPVT, etc.)
3%e5%
Others 3%e20%observed.6 The second mechanism by which coronary artery
disease leads to SCD is scar-related VT. Scar formation after
myocardial infarction represents an important structural
prerequisite for reentry creating unidirectional block and
areas of slow conduction. This is reflected in studies with
cardiac magnetic resonance imaging where heterogeneity of
the scar is a strong predictor of ventricular arrhythmias.19 The
incidence of SCD due to coronary artery disease has been
reduced by better revascularization and the use of ACE in-
hibitors, beta blockers, and statins.
Hypertension predisposes independently to SCD via left
ventricular hypertrophy (LVH). Left ventricular hypertrophy
determined from ECG or echocardiography predicts an
increased risk of SCD. Similar to hypertrophic cardiomyopa-
thy, in severe LVH, loss of parallel orientation of myofibers
and a resulting disarray may cause VT or VF. LVH at a late
stage may also be eccentric with severely reduced ejection
fraction. Hypertension seems to be of particular importance
as a cause of SCD in black Africans. This may be due to a
greater prevalence of hypertension in black compared with
white men or due to a more difficult control of blood pressure
resulting in more advanced LVH.
Dilated cardiomyopathy (DCM) is a highly heterogeneous
group of non-ischemic diseases that all result in severely
reduced left ventricular function. SCD in DCM is most
frequently caused by ventricular tachyarrhythmia (approxi-
mately 50%), particularly VF, but can also be due to brady-
cardia and electromechanical dissociation. The incidence of
SCD in DCM has been drastically reduced by treatment with
beta blockers, ACE inhibitors and other drugs. Annual mor-
tality in DCMwas up to 30% in the era before these drugs were
used but as low as 7% at the time that studies such as SCD-
HeFT or DEFINITE were performed.20,21
If SCD occurs in the absence of coronary artery disease or
heart failure, the main causes are hypertrophic (HCM) and
arrhythmogenic right ventricular cardiomyopathy (ARVC).
Most data on the incidence of SCD in younger, seemingly
healthy patients stem from studies analyzing SCD in
athletes.22,23
In Minneapolis Heart Institute Foundation Registry, car-
diovascular causes of SCD were assessed in 1435 young ath-
letes in the period between 1980 and 2005. HCM was found in
44% of cases of SCD.22 The second largest cause in this registry
was coronary artery anomalies including a tunneled LAD and
coronary artery disease (together 23%). ARVCwas found as the
cause of SCD in 4% of patients, all channelopathies taken
together in 3%.
HCM predisposes to SCD due to myocardial hypertrophy,
myocyte disarray and fibrosis. Apart from direct proar-
rhythmia, these changes can lead to SCD secondary to
myocardial ischemia, diastolic dysfunction, left ventricular
outflow obstruction and development of congestive heart
failure.
European data from a North Italian registry show a
different distribution.23 In 269 cases of SCD from 1979 to 1996
in persons aged <35 years, HCM accounted for 7% of SCD in
non athletes compared to only 2% in athletes, demonstrating
a different incidence of HCM in different populations and
potentially the effect of screening competitive athletes for
HCM.
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11% of cases of SCD. The pathognomonic finding in ARVC is a
diffuse or segmental loss of right ventricular myocytes
replaced by fibro-fatty tissue and thinning of the right ven-
tricular wall. These changes predispose to slow conduction,
presence of diastolic potentials, and unidirectional block.
Therefore, SCD, usually by VT that degenerates into VF, is
frequent in ARVC (annual mortality approximately 2.3%).24
Additionally, the development of right heart failure and left
ventricular dysfunction increase the risk of SCD in ARVC.
2.3. Sudden cardiac death (SCD) in patients without
structural heart disease
In about 5%e10% of cases of SCD, no underlying heart disease
can be found at autopsy. Some of these (may be 50%) can be
explained by genetic disorders that lead to ion channel
dysfunction (“channelopathies”) or other abnormalities in the
formation of the action potential.
Brugada syndrome accounts for approximately 20% of SCD
in patients with structural normal hearts.25 It is characterized
in the ECG by a coved-type ST-segment elevation in the right
precordial leads. Brugada syndrome is caused by a genetic
change of the sodium channel which causes loss of the action
potential dome in the epicardium but not in the endocardium.
This is seen in the ECG as a coved type ST-segment elevation
in leads V1 and V2. It generates a transmural gradient that
predisposes to local phase 2 reentry which in turn causes
short-coupled ventricular premature beats, polymorphic VT
and VF.25,26 The typical arrhythmia leading to SCD in Brugada
syndrome is therefore VF. It can be triggered by sodium
channel blockers, fever, vagotonic agents, beta blockers, anti-
depressants, hypokalemia and other conditions. SCD in Bru-
gada syndrome occurs typically during sleep or at rest.
The long QT syndrome (LQTS) consists of a number of
familial diseases with genetic variations of different potas-
sium and sodium channels. All have in common a prolon-
gation of the QT or QTc interval, respectively. This may,
however, not be permanently visible from the ECG. Of the
many types of LQTS, LQTS1-3 are clinically the most impor-
tant. LQTS1 is the most frequent subtype and explains 30%e
35% of cases.27 SCD in LQTS1 usually occurs when sympa-
thetic stimuli are present such as physical activity (particu-
larly swimming and diving into cold water) or emotional
stress. LQTS2 is the second most frequent subtype and ac-
counts for 25%e30% of LQTS cases. SCD in LQTS2 frequently
occurs in response to emotional stress and particularly sud-
den auditory stimuli such as ringing of an alarm clock or a
telephone. Women in the postpartum period are specifically
susceptible. In LQTS2, up to 20% of patients have a non-
diagnostic ECG. LQTS3 is present in 5%e10% of LQTS pa-
tients who are at increased risk of SCD during bradycardia,
specifically during sleep. Characteristically, ventricular ar-
rhythmias in LQTS3 are particularly lethal.
The SCD risk before 40 years of age is >50% when QTc is
>500 ms in LQTS1, LQTS2, and in males with LQTS3.2 In an
international LQTS registry, the risk of SCD was associated
with a QTc >530 ms, history of syncope in the past 10 years,
and gender (10e12-year-old boys had a higher risk than girls,
in the 13e20 age range, the risk was comparable28).Symptomatic patients have a yearly mortality rate of 20% and
10-year mortality of 50% after a first event of ventricular
arrhythmia if no treatment is installed.
The characteristic ventricular arrhythmia in LQTS is TdP,
typically triggered by a short-long-short cycle (e.g. ventricular
bigeminus with long post-extrasystolic interval). To combine
the information from the resting ECG, ventricular arrhythmia,
clinical and familial history in order to establish an LQTS
diagnosis, the Schwartz score has been developed.29
A large number of drugs used in different medical in-
dications can induce LQTS such as antibiotics, other anti-
infectives, anti-parkinson drugs, anti-depressants, chemo-
therapy agents, neuroleptics, etc. Because SCD due to QT
prolongation by non-antiarrhythmic drugs occurs in
<1:10,000e1:100,000 exposed patients, the risk of drug-
induced LQTS can remain undetected in clinical studies
even if >5000 patients are enrolled.30 Therefore, some drugs
have been removed from the market after many years of use,
such as astemizole and cisaprid. Antipsychotic drugs have a
more than three fold increase in the risk of SCD. A perma-
nently updated list of drugs with a risk of QT prolongation can
be found e.g. at www.qtdrugs.org and www.crediblemeds.org.
Female gender, hypocalcemia, hypomagnesemia, brady-
cardia, heart failure, postcardioversion, atrial fibrillation and
left ventricular hypertrophy can predispose to drug-induced
QT prolongation. The channel that typically interacts with
drugs is IKr.27 In asymptomatic carriers of LQTS mutations,
undetected LQTS can manifest itself with TdP and SCD upon
receiving QT prolonging drugs.
The short QT syndrome (SQTS) is a rare inherited chan-
nelopathy associatedwith SCD and atrial fibrillation.31 Several
gain-of-function (potassium channels) and loss-of-function
mutations (L-type calcium channel subunits) have been
discovered. A QTc interval shortened to <360 ms, shortened
ventricular refractory periods, and increased dispersion of
repolarization predispose to reentry.
Catecholaminergic polymorphic VT (CPVT) is an inherited
arrhythmogenic disorder characterized by adrenergically
mediated polymorphic VT.32 The mean age at manifestation
is 7e9 years (in some studies at 12 years), 80% of patients
have their first event at an age <40 years.33 SCD is typically
induced by stress, physical or emotional. It almost never
occurs at rest without a specific trigger.32,34 Patients with
CPVT have a higher risk of SCD than patients with LQTS. The
baseline ECG is usually unremarkable, while the ventricular
tachyarrhythmia is characteristically a bidirectional VT, a
tachycardia in which the axis of QRS complexes alternates.
Polymorphic, bidirectional VT is usually easily inducible by
exercise stress test, in some cases even by talking to the
patient. There is a typical pattern of arrhythmia development
progressing from a single ventricular premature beats to
couplets and finally to a bidirectional polymorphic VT. Also
supraventricular tachyarrhythmias and short runs of atrial
fibrillation are common.
In CPVT, ryanodine receptor mutations have been identi-
fied that lead to uncontrolled calcium release from the
sarcoplasmic reticulum.32 Even though CPVT has a genetic
etiology, most reported cases are sporadic, potentially due to
the high lethality and to the fact that patients may not reach
reproductive age unless correctly diagnosed and effectively
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tory of SCD at young age during adrenergic stress.
Recently, research has focused on the clinical meaning of
early repolarization (ER). An ER pattern is characterized by J
point elevation, distinct J waves with andwithout ST-segment
elevation and slurring of the terminal part of the QRS in
inferior limb and lateral precordial leads, and a combination
of J wave, J point and ST-segment elevation, and a gigantic J
wave.35,36 An ER pattern is commonly found in healthy young
males and has been regarded as benign. However, experi-
mental data showed that phase 2 reentry can easily be initi-
ated in ER and trigger polymorphic VT or VF.37,38 With a
prevalence of 1%e13% in the general population,39e42 ER is an
insensitive ECG sign for an increased risk of SCD. Subgroups of
ER patterns have been identified that have an increased risk of
SCD: horizontal or descending ER0.1mV (relative risk 1.4343),
ER 0.1 mV in the inferior leads (relative risk 1.5856), ER
0.2 mV in inferior leads with horizontal/descending ST-
segment variant (relative risk 3.14.43) ER in form of slurring
and notching were also associated with a higher SCD risk
(relative risk 1.48e2.0944,45). ER with ascending ST conveyed
no increased risk of SCD.43 The observation of ER in the ECG
becomes important in context with syncope ora family history
of SCD. Similar to Brugada syndrome, the ER pattern may be
variable and J waves can be very small during normal sinus
rhythm, bigger during increased vagal tone and bradycardia,
and still further accentuated following successive extrasys-
toles, and biggest after compensatory pauses that can cause
short-long-short sequences and induce VT/VF.37,46,47
The exact electrophysiologic basis for ER is not well un-
derstood to date. Transmural gradients generated in response
to ICa loss-of-function or IK-ATP gain-of-function could
manifest in the ECG as a diversity of ER patterns.35 The
phenotype depends on the part of the heart that is principally
affected and the ion channels involved. Prominent J waves in
some ER syndromes may predispose to phase 2 reentry.36,37
In a number of young patients, SCD occurs in the absence
of structural heart disease, any ECG signs of underlying cause
(e.g. cove-type ST elevation, epsilon wave, elevated J point,
QTc duration abnormality), and any identifiable genetic syn-
dromes. In a wider sense, this is commonly referred to as
idiopathic VF. No firm data exist (by definition) about the un-
derlying mechanisms of idiopathic VF.
2.4. Sudden cardiac death (SCD) in patients with an
implanted defibrillator
Depending on the severity of the underlying heart disease and
comorbidity, patients with an implanted cardioverter-
defibrillator (ICD) have a varying annual mortality, lowest
(<1%) in young patients without structural heart disease, and
highest (>7%) in patients with heart failure (particularly
ischemic heart disease) and a defibrillator for cardiac
resynchronization therapy (CRT-D). A rather low proportion of
ICD patients die from SCD, e.g. in electrical storm or due to
device dysfunction.48 However, arrhythmic, non-sudden
death due to recurrent ventricular tachyarrhythmias, slow
VT, etc. may add substantially tomortality in ICD patients.49 A
higher NYHA functional class, a history of spontaneous or
inducible VT and amiodarone therapy have been reported asrisk factors for arrhythmic death in ICD patients.49 Patients
dying from arrhythmic causes had more VT/VF events during
follow up suggesting the presence of a more unstable elec-
trical substrate.51
Immediately before the onset of VT or VF in ICD patients,
an elevation of the J point has been observed in studies using
the ICD can for subcutaneous far field electrogram
recording.50 This may indicate that electrical instability and
phase 2 reentry play a role in VT or VF in ICD patients.503. Electrophysiologic mechanisms of
ventricular tachyarrhythmia
The basic electrophysiologic mechanisms leading to ventric-
ular tachyarrhythmias (VT or VF) can be divided into three
groups: 1. Abnormal automaticity, 2. Triggered activity, 3.
Reentry.
3.1. Abnormal automaticity
In abnormal ventricular automaticity, ventricular myocardial
cells generate a spontaneous repetitive depolarization at a
rate higher than that of normal automaticity. The underlying
mechanism is usually a reduced resting membrane potential
in the range between 70 and 30 mV. The more depolarized
the resting potential, the faster the rate of abnormal auto-
maticity. Abnormal depolarization of membrane potential is
commonly a result of increased extracellular potassium, a
reduced number or function of IK1 channels, or electrotonic
influence of neighboring cells in the depolarized zone.35 Hy-
pokalemia can lead to a major reduction in IK1, causing de-
polarization and the development of enhanced or abnormal
automaticity, particularly in Purkinje fibers. Adrenergic ac-
tivity can increase abnormal automaticity. Also a changed
threshold for sodium influx can be responsible for a reduced
resting membrane potential. The typical ECG correlated with
abnormal automaticity is an accelerated idioventricular
rhythm. Among others, abnormal automaticity plays a role as
a mechanism of SCD in acute ischemia, myocarditis, and
intoxication (e.g. cocaine). Abnormal automaticity primarily
causes VT at any rate that can secondarily degenerate into VF.
3.2. Triggered activity
Triggered activity follows the cardiac action potential and
depends on preceding transmembrane activity. There are two
subclasses of membrane potential oscillations, referred to as
after depolarizations: early after depolarizations (EADs) and
delayed after depolarizations (DADs). Early after depolariza-
tion (EAD) or DAD amplitudes that are sufficiently high to
reach the membrane threshold result in a spontaneous action
potential referred to as a triggered response. These triggered
events give rise to extrasystoles, which can precipitate
tachyarrhythmias.
EADs occur during phase 2 or 3 of the action potential,
typically at slow heart rates. They develop when the balance
of current during phase 2 and 3 of the action potential shifts in
the inward direction.51 If the change results in a net inward
current during the plateau of membrane potentials, it leads to
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cells and Purkinje fibers, less in epicardial or endocardial cells.
This difference is pronounced if the heart is exposed to drugs
that prolong the action potential51 because IKs is weaker and
late Ina stronger in M cells.52,53 The risk of development of
EADs depends on the availability of IKr and IKs. Inmany forms
of cardiomyopathy, EADs can appear in any part of the ven-
tricular myocardium due to a reduced availability of IKr and
IKs.
EADs are typical mechanism of TdP and polymorphic VT in
LQTS. They are also observed in cardiac tissue injury, elec-
trolyte dysbalance, hypoxia, acidosis, ventricular hypertrophy
and heart failure. EADs represent the typical mechanism of
proarrhythmia by a number of drugs that inhibit potassium
currents or increase inward currents. Class III antiarrhythmic
drugs can induce EADs at slow heart rates. In contrast,
catecholamine-induced EADs require a fast heart rate.54
Delayed after depolarizations (DADs) occur in phase 4 after
full repolarization, in contrast to EADsalwaysat relativelyhigh
heart rates. DADs are observed in situations with increased
intracellular calcium, e.g. digitalis- or catecholamine-
induced.54e56 They occur in ventricular hypertrophy, heart
failure, Purkinje fibers that survived myocardial infarction,
and are the typical mechanism of ventricular outflow tract
tachycardias. Particularly bidirectional ventricular tachy-
cardia in CPVT is caused by DADswhere the “leaky” ryanodine
receptor leads to calcium overload during catecholamine
stimulation. Also in digitalis-induced calcium overload, DADs
can cause bidirectional ventricular tachycardia.
3.3. Reentry
In circus movement reentry, the activation wavefront propa-
gates around an anatomic or functional obstacle and reexcites
the site of origin. In this type of reentry, all cells recover from
excitation and can be excited again when the next wavefront
arrives. In contrast, in reflection and phase 2 reentry large dif-
ferences of recovery from refractoriness exist between
different sites. Thesitewithdelayedrecoveryexcites its already
recovered neighbor, resulting in a reentrant reexcitation.
Reentry can be classified as anatomic or functional, with an
overlap in which both are important in creating reentry.51
Circus movement reentry requires three conditions: 1.
Unidirectional block, allowing the circulating wave to travel in
one direction only, 2. Conduction block (fixed or functional),
and 3. Areas of slow conduction where the tachycardia cycle
length is longer than the longest refractory period of the circle
to allow each site in the circuit to recover before the return of
the circulating wave.57 Additionally, the excitatory wavemust
progress along a distinct pathway, return to its point of origin
and then follow the same path again. Interruption of the
reentrant circuit at any point along its path should terminate
the circus movement. Conduction velocity and refractoriness
determine if reentry can be established. The length of the
reentry circuit must be longer or equal to the wavelength. e.g.
the product of conduction velocity and refractory period.
Reduction of conduction velocity (e.g. by antiarrhythmic
drugs) can therefore facilitate reentry.
Reentry in circus movements typically requires a specific
substrate (e.g. scar or diseased myocardium) and occurs inischemic and non-ischemic myocardial disease. However,
reentry can also occur without anatomic obstacles as “func-
tional reentry”. Premature impulses can propagate only in the
direction of shorter refractory periods, create an arc of block
around which the impulse circulates and reexcite its site of
origin.58 In this “leading circle model”, tachycardia is not
readily influenced by stimuli from areas outside the reentrant
circuit and thus may be difficult to entrain. In the spiral wave
concept, circulating waves are considered in the absence of an
anatomic obstacle asmechanisms of functional reentry.59 The
term spiral wave describes reentrant activity in 2 dimensions,
e.g. from epicardium to endocardium. Spiral wave activity
explains the ECG patterns of monomorphic and polymorphic
VTs and VF. In monomorphic VT, the spiral wave is anchored
and does not drift within the ventricular myocardium. In
polymorphic VT and VF, the spiral wave drifts within the
ventricular myocardium.60 The spiral wave concept explain
the degeneration of VT into VF: When a single spiral wave
responsible for VT breaks up, multiple spirals that drift can
occur that are continuously extinguished and recreated.61
In postmyocardial infarction tissue, figure 8 reentry can
occur in the surviving epicardial layer that overlies an area of
infarction.62 In the figure 8 model, a wavefront circulates in
both directions around a line of conduction block rejoining on
the distal side of the block. The wavefront then breaks
through the arc of block to reexcite the tissue proximal to the
block. The reentrant activation continues as 2 circulating
wavefronts that travel in clockwise and counterclockwise di-
rections around the two arcs.
Reentry can occur without circus movement by the
mechanisms “reflection” and “phase 2 reentry”. In the concept
of reflection, slow anterograde conduction of the impulse in
Purkinje fibers is followed by a retrograde wavefront that
produces a “return extrasystole”.63,64 Reflection results from
the to and fro electrotonically mediated transmission of the
impulse across the same in excitable segment and generates a
closely coupled reflected reentry.65,66 Reflected reentry has
been demonstrated in isolated atrial and ventricular
myocardial tissues and in Purkinje fibers.
Also phase 2 reentry does not depend on circus movement
and can appear to be of focal origin. Phase 2 reentry occurs
when the dome of the action potential, most commonly
epicardial, propagates from sites at which it is maintained to
sites at which it is abolished, causing local reexcitation of the
epicardium and the generation of closely coupled extrasys-
tole. Severe spatial dispersion of repolarization is needed for
phase 2 reentry. Phase 2 reentry has been proposed as the
mechanism responsible for the closely coupled extrasystole
that precipitates VT/VF in Brugada and early repolarization
syndromes.4. Conclusion
Our understanding of SCD has dramatically improved and
multiple mechanisms have been identified on the levels of
genes, cellular and clinical electrophysiology. Many of these
findings have reinforced the importance of fundamental
knowledge about the ECG to identify patients at risk and
prevent SCD by drugs, ablation and ICD implantation.
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